In recent decades, several exploratory studies (26–28) have shown that doxorubicin combined with other antineoplastic agents, in particular with the alkylating agent, may increase response rates or/and median PFS with increased AEs but fail to improve OS; although olaratumab (a PDGFR inhibitor) plus doxorubicin had a greater median OS than doxorubicin alone in advanced STS in the Phase IB/II study (29) (26.5 months vs. 14.7 months). This evidence concerns the gene PDGFRB and telomere syndrome.